BLFS

SEC source: 0001144204-18-000672 · tv482650_4.xml · nonDerivative · entry 2

Hinson Andrew G · CIK 0001389410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,319

F2 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $5,625 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-18-000667 · tv482648_4.xml · nonDerivative · entry 2

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus

Disclosed balance after: 2,824,677

F2 · price: The shares of common stock were issued to Taurus pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of the reporting person receiving $5,000 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-18-000662 · tv482647_4.xml · nonDerivative · entry 2

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,623

F2 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $6,250 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-18-000679 · tv482658_4.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Sr. VP & Chief Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 151,738

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001144204-18-000678 · tv482657_4.xml · nonDerivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 139,517

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001144204-18-000677 · tv482656_4.xml · nonDerivative · entry 1

DE GREEF RODERICK · CIK 0001241181 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,583

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001144204-18-000676 · tv482655_4.xml · nonDerivative · entry 1

Mathers James · CIK 0001676166 · Vice President, Global Sales

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,167

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001144204-18-000675 · tv482654_4.xml · nonDerivative · entry 1

COHEN RAYMOND W · CIK 0001258288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,531

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F2 · balance_after: Since the date of the reporting person's last ownership report, he transferred 10,537 shares of the issuer's common stock and options to purchase 21,425 shares of the issuer's common stock to his ex-wife pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-wife.

SEC source: 0001144204-18-000673 · tv482652_4.xml · nonDerivative · entry 1

Berard Todd · CIK 0001633186 · Vice President, Marketing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,583

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001144204-18-000674 · tv482653_4.xml · nonDerivative · entry 1

Foster Karen A. · CIK 0001683151 · Vice President, Operations

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,917

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001144204-18-000672 · tv482650_4.xml · nonDerivative · entry 1

Hinson Andrew G · CIK 0001389410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,381

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001144204-18-000667 · tv482648_4.xml · nonDerivative · entry 1

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus

Disclosed balance after: 2,823,843

F1 · shares: The restricted stock was granted to Taurus4757 GmbH ("Taurus"), a wholly owned entity of the reporting person, pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted to Taurus4757 GmbH ("Taurus"), a wholly owned entity of the reporting person, pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001144204-18-000662 · tv482647_4.xml · nonDerivative · entry 1

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,581

F1 · shares: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments.

SEC source: 0001144204-17-051157 · v476392_4.xml · nonDerivative · entry 1

Hinson Andrew G · CIK 0001389410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,381

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $5,625 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-17-051154 · v476391_4.xml · nonDerivative · entry 1

COHEN RAYMOND W · CIK 0001258288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,068

F1 · security: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $18,750 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $18,750 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-17-051153 · v476390_4.xml · nonDerivative · entry 1

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus

Disclosed balance after: 2,813,843

F1 · price: The shares of common stock were issued to Taurus4757 GmbH ("Taurus"), a wholly owned entity of the reporting person, pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of the reporting person receiving $5,000 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-17-051152 · v476389_4.xml · nonDerivative · entry 1

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,581

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $6,250 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-17-036096 · v470495_4.xml · nonDerivative · entry 1

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,473

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $6,250 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-17-036094 · v470493_4.xml · nonDerivative · entry 1

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus

Disclosed balance after: 2,812,956

F1 · price: The shares of common stock were issued to Taurus4757 GmbH ("Taurus"), a wholly owned entity of the reporting person, pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of the reporting person receiving $5,000 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-17-036093 · v470492_4.xml · nonDerivative · entry 1

COHEN RAYMOND W · CIK 0001258288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,743

F1 · security: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $18,750 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $18,750 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-17-036092 · v470491_4.xml · nonDerivative · entry 1

Hinson Andrew G · CIK 0001389410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,384

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $5,625 of director fees for the quarter at a price per share based upon the closing stock price of the issuer's common stock on the last day of the quarter.

SEC source: 0001144204-17-036095 · v470494_4.xml · nonDerivative · entry 1

VILLIGER WALTER · CIK 0001113655 · 10% owner

WAVI Holding AG · CIK 0001603260 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By WAVI Holdings AG

Disclosed balance after: 4,250

F1 · kind: The shares of Series A nonconvertible preferred stock were issued on July 5, 2017 to WAVI Holdings AG, a wholly owned entity of the reporting person ("WAVI"), in exchange for the cancellation of a previously issued promissory note of the issuer in the name of WAVI in the amount of $4,250,000 including principal and accrued interest thereon through June 1, 2017. Such exchange was pursuant to an agreement between the issuer and WAVI dated June 30, 2017.

F1 · price: The shares of Series A nonconvertible preferred stock were issued on July 5, 2017 to WAVI Holdings AG, a wholly owned entity of the reporting person ("WAVI"), in exchange for the cancellation of a previously issued promissory note of the issuer in the name of WAVI in the amount of $4,250,000 including principal and accrued interest thereon through June 1, 2017. Such exchange was pursuant to an agreement between the issuer and WAVI dated June 30, 2017.

SEC source: 0001144204-17-032418 · v468960_4.xml · derivative · entry 2

Mathew Aby J. · CIK 0001556355 · Sr. VP & Chief Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 24,285 shares

Expires 2017-08-07

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option was exercisable in four equal annual installments commencing on 08/07/2008.

SEC source: 0001144204-17-032418 · v468960_4.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Sr. VP & Chief Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,530

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-17-029845 · v467956.xml · derivative · entry 2

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 71,429 shares

Expires 2017-05-29

SEC source: 0001144204-17-029845 · v467956.xml · nonDerivative · entry 1

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus

Disclosed balance after: 2,810,864

F1 · ownership.nature: The shares of common stock were issued to Taurus4757 GmbH, a wholly owned entity of the reporting person, upon exercise of the warrants held by the reporting person.

SEC source: 0001144204-17-029661 · v467872_4.xml · derivative · entry 2

VILLIGER WALTER · CIK 0001113655 · 10% owner

WAVI Holding AG · CIK 0001603260 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 71,429 shares

Expires 2017-05-29

SEC source: 0001144204-17-029661 · v467872_4.xml · nonDerivative · entry 1

VILLIGER WALTER · CIK 0001113655 · 10% owner

WAVI Holding AG · CIK 0001603260 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By WAVI Holdings AG

Disclosed balance after: 3,747,503

F1 · ownership.nature: The shares of common stock were issued to WAVI Holdings AG, a wholly owned entity of the reporting person, upon exercise of the warrants held by the reporting person.

SEC source: 0001144204-17-019306 · v463692_4.xml · nonDerivative · entry 1

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,858

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $6,250 of director fees for the quarter.

SEC source: 0001144204-17-019305 · v463691_4.xml · nonDerivative · entry 1

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus

Disclosed balance after: 2,739,435

F1 · price: The shares of common stock were issued to Taurus4757 GmbH ("Taurus"), a wholly owned entity of the reporting person, pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of the reporting person receiving $5,000 of director fees for the quarter.

SEC source: 0001144204-17-019304 · v463690_4.xml · nonDerivative · entry 1

Hinson Andrew G · CIK 0001389410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,030

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $5,625 of director fees for the quarter.

SEC source: 0001144204-17-019371 · v463694_4.xml · nonDerivative · entry 1

COHEN RAYMOND W · CIK 0001258288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,898

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $18,750 of director fees for the quarter.

SEC source: 0001144204-17-007173 · v458958_4.xml · derivative · entry 1

Rice Michael · CIK 0001389512 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 100,000

Underlying: Common Stock · 100,000 shares

Expires 2022-02-17

F1 · derivative.exercise_date: The options vest 25% on the first anniversary of the grant date and thereafter, in 36 equal monthly installments.

SEC source: 0001144204-17-007172 · v458957_4.xml · derivative · entry 2

Mathew Aby J. · CIK 0001556355 · Sr. VP & Chief Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,714 shares

Expires 2017-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-17-007172 · v458957_4.xml · nonDerivative · entry 1

Mathew Aby J. · CIK 0001556355 · Sr. VP & Chief Tech. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,245

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-17-007171 · v458956_4.xml · derivative · entry 2

Hinson Andrew G · CIK 0001389410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,857 shares

Expires 2017-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-17-007171 · v458956_4.xml · nonDerivative · entry 1

Hinson Andrew G · CIK 0001389410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,351

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-17-007170 · v458955_4.xml · derivative · entry 2

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,857 shares

Expires 2017-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-17-007170 · v458955_4.xml · nonDerivative · entry 1

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus

Disclosed balance after: 2,737,054

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · ownership.nature: The shares of common stock were issued to Taurus4757 GmbH, a wholly owned entity of the reporting person, upon exercise of the options held by the reporting person.

SEC source: 0001144204-17-007169 · v458954_4.xml · derivative · entry 2

COHEN RAYMOND W · CIK 0001258288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,857 shares

Expires 2017-02-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-17-007169 · v458954_4.xml · nonDerivative · entry 1

COHEN RAYMOND W · CIK 0001258288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,969

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001144204-17-002794 · v456516_4.xml · nonDerivative · entry 1

Schick Joseph C · CIK 0001592238 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,882

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $6,250 of director fees for the quarter.

SEC source: 0001144204-17-002793 · v456510_4.xml · nonDerivative · entry 1

Hinson Andrew G · CIK 0001389410 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,494

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $5,625 of director fees for the quarter.

SEC source: 0001144204-17-002792 · v456506_4.xml · nonDerivative · entry 1

COHEN RAYMOND W · CIK 0001258288 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,112

F1 · price: The shares of common stock were issued to the reporting person pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of receiving $18,750 of director fees for the quarter.

SEC source: 0001144204-17-002791 · v456505_4.xml · nonDerivative · entry 1

GIRSCHWEILER THOMAS · CIK 0001273547 · Director · 10% owner

Taurus4757 GmbH · CIK 0001603397 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Taurus4757 GmbH

Disclosed balance after: 2,719,197

F1 · price: The shares of common stock were issued to Taurus4757 GmbH ("Taurus"), a wholly owned entity of the reporting person, pursuant to the BioLife Solutions 2013 Performance Incentive Plan in lieu of the reporting person receiving $5,000 of director fees for the quarter.